Retinal Surgery

Christina Weng, MD, MBA, FASRS, explores the viability of postoperative day 0 exams as a substitute for day 1 after vitreoretinal surgery, revealing promising findings.

Insights on injection technique and the future potential of SCS treatments.

Looking at innovative tools and their applications in different disease states can help to think creatively about ways to benefit patients in retina care.

The LYNX LIO is the latest generation of pattern scanning lasers that were first introduced in 2006.

Pykus Therapeutics reveals promising results for PYK-2101, a retinal sealant that enhances recovery and improves patient experience in retinal detachment surgery.

KIO-104 is a therapeutic candidate shown to significantly reduce retinal scar formation.

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.

Tertiary syphilis, which can develop years to decades after the initial infection, is characterized by chronic inflammatory damage affecting multiple organ systems.

The recent agreement with Cipla adds to the list of partnerships Formosa has formed for APP13007.

PYK-2101 is a first-in-class biodegradable retinal hydrogel sealant.

Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery.

The researchers successfully tested the robot using enucleated pig eyes.

The role of compounded anesthetic formulations in streamlining efficiency and elevating patient care.

The pandemic caused an overall decrease in the rates of the 10 most common ophthalmic procedures performed in 2020 when compared to the year prior.

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

The Belgian B Corp company, founded in 2016, is partially owned by Rayner and distributed in over 20 European countries.

The Foundation has assembled a multidisciplinary team of leading scientists, researchers, and physicians from multiple institutions, all focused on accelerating convergent technologies.

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for oculoplastic procedures from August 2018 to November 2020.

Vaidehi S. Dedania, MD, from the New York University (NYU) Langone Health and the Grossman School of Medicine, spoke with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. She insights from the session, "Preventing and managing complications following vitreoretinal surgery."

Vikas Chopra, MD, from the Doheny Eye Institute of UCLA, caught up with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. He shared how technology has advanced ophthalmic surgery over the years and how hands on sessions at the meeting allow surgeons to train for rare complications that can arise during routine surgeries.

Michael Singer, MD, shared insights from on his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the effectiveness of gel versus traditional drops.

At this year's American Academy of Ophthalmology (AAO) meeting, Jonathan Brugger, MD, spoke about the changing approach to epimacular membranes and the use of brilliant blue in the procedure.

This initiative is supported by a $5 million grant from the Knights Templar Eye Foundation.

Marketed as Triesence, it is a preservative-free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

Carl Awh, MD, FASRS, spoke about the presence of members of the American Society of Retina Specialists (ASRS) attending the EURETINA meeting and the value of the international community of retina clinicians connecting at meetings around the globe.

Zhang’s journey as the first retina optometrist in Colorado